Regeneron Pharmaceuticals (NASDAQ:REGN) Upgraded to Strong-Buy at Wolfe Research

Wolfe Research upgraded shares of Regeneron Pharmaceuticals (NASDAQ:REGN) to a strong-buy rating in a research note released on Thursday morning,Zacks.com reports.

Several other analysts have also issued reports on REGN. Evercore ISI cut their price target on Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an “outperform” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating for the company in a research note on Friday, November 1st. JPMorgan Chase & Co. decreased their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating on the stock in a research note on Thursday, October 24th. Piper Sandler dropped their price target on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an “overweight” rating for the company in a research report on Friday, November 1st. Finally, Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $1,137.00 to $1,126.00 and set a “buy” rating for the company in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $1,099.55.

Regeneron Pharmaceuticals Stock Performance

Shares of NASDAQ REGN opened at $756.81 on Thursday. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09. Regeneron Pharmaceuticals has a 12-month low of $753.69 and a 12-month high of $1,211.20. The firm has a market capitalization of $83.17 billion, a price-to-earnings ratio of 18.73, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. The firm has a 50 day moving average of $985.21 and a 200 day moving average of $1,034.89.

Insider Buying and Selling at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, CFO Christopher R. Fenimore sold 5,680 shares of the business’s stock in a transaction dated Wednesday, August 28th. The shares were sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the transaction, the chief financial officer now directly owns 15,305 shares in the company, valued at $18,447,575.65. The trade was a 27.07 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 7.48% of the stock is owned by insiders.

Institutional Trading of Regeneron Pharmaceuticals

Institutional investors and hedge funds have recently bought and sold shares of the stock. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% during the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in Regeneron Pharmaceuticals during the 2nd quarter worth approximately $26,000. Sachetta LLC grew its stake in shares of Regeneron Pharmaceuticals by 71.4% in the second quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after acquiring an additional 10 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth $26,000. Finally, Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the first quarter valued at $28,000. 83.31% of the stock is currently owned by hedge funds and other institutional investors.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.